Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 17 de 17
1.
Front Med (Lausanne) ; 9: 839475, 2022.
Article En | MEDLINE | ID: mdl-35317326

Transfusion of granulocyte concentrates (GC) is an alternative therapy for neutropenic patients with life-threatening infections. While neutrophils are the main source of antimicrobial activity, only neutrophil numbers are used to certify GCs. The objective of this study was thus to functionally characterize neutrophils in GCs prepared by leukapheresis from G-CSF-stimulated donors and compare to the less characterized prednisone GCs. GCs prepared from healthy donors stimulated with prednisone and then G-CSF after a 6-month washout period were analyzed prior to and after leukapheresis, and after storage. Leukocyte composition, neutrophil viability, calcium mobilization, chemotaxis, phagocytosis, reactive oxygen species, cytokine production and metabolites were determined. G-CSF GCs contained significantly more neutrophils than prednisone GCs of which 40% were immature. In comparison to non-stimulated healthy donor neutrophils, prednisone GC neutrophils exhibited enhanced phagocytosis and G-CSF GC neutrophils showed decreased chemotaxis but increased IL-8 production. Leukapheresis altered prednisone GC neutrophil responses. Storage had a significant, negative impact on G-CSF GC neutrophils compared to prednisone GC neutrophils. G-CSF and prednisone GC neutrophils thus differ in maturity and function, and G-CSF GC neutrophils are more sensitive to storage. Functional testing of GC neutrophils and better storage conditions would improve the quality of this blood product.

2.
Exp Hematol ; 42(9): 741-52.e1, 2014 Sep.
Article En | MEDLINE | ID: mdl-24793546

Strategies to enhance the expansion of umbilical cord blood hematopoietic stem and progenitor cells (HSPCs) are crucial to enable their widespread application to adults and to overcome important limitations, such as delayed engraftment. Osteoblasts regulate HSPCs under steady-state and also under stress conditions, when HSPCs undergo numerous cycles of expansion. We hypothesized that osteoblasts could provide better stimulation for the expansion of multipotent HSPCs and subsequent hematopoietic recovery than mesenchymal stromal cells. Hence, we assessed the growth and engraftment modulatory activities of mesenchymal stromal cell-derived osteoblasts (M-OSTs) on hematopoietic progenitors. Mesenchymal stromal cells and M-OSTs favored the maintenance of CD34(+) cells. The expansion of cord blood CD34(+) cells and myeloid progenitors was highest in cultures supplemented with unfiltered M-OST-conditioned medium (M-OST CM). In addition, increased expression of cell surface receptors important for the homing of progenitors to the bone marrow, C-X-C chemokine receptor type 4 and lymphocyte function-associated antigen 1, was observed in CM-based cultures. Additionally, M-OST CM positively modulated the engraftment properties of expanded progenitors. Most notably, although human platelet levels remained steady in the first 2 weeks in mice transplanted with HSPCs expanded in standard medium, levels in mice transplanted with M-OST CM HSPCs rose continuously. Consistent with this, short-term human progenitor reconstitution was consistently greater in M-OST recipients. Finally, cytokine array-based profiling revealed increases in insulin-like growth factor binding protein 2, chemokines, and myeloid stimulating cytokines in M-OST CM. In conclusion, this study suggests that M-OSTs represent a new underappreciated source of feeder cells for the expansion of HSPCs with enhanced thrombopoietic activity.


Cell Proliferation , Fetal Blood/metabolism , Hematopoietic Stem Cells/metabolism , Mesenchymal Stem Cells/metabolism , Multipotent Stem Cells/metabolism , Osteoblasts/metabolism , Adult , Animals , Cells, Cultured , Culture Media, Conditioned/pharmacology , Female , Fetal Blood/cytology , Hematopoietic Stem Cell Transplantation , Hematopoietic Stem Cells/cytology , Heterografts , Humans , Male , Mesenchymal Stem Cells/cytology , Mice , Mice, Inbred NOD , Multipotent Stem Cells/cytology , Osteoblasts/cytology
3.
Methods Mol Biol ; 946: 205-24, 2013.
Article En | MEDLINE | ID: mdl-23179834

Megakaryocytes (MK) are hematopoietic cells present in the bone marrow that are responsible for the production and release of platelets in the circulation. Given their very low frequency (<1%), human MK often need to be derived in culture to study their development or to generate sufficient material for biological studies. This chapter describes a simplified 14-day culture protocol that efficiently leads to the production of MK and platelets from cord blood enriched progenitor cells. A serum-free medium is suggested for the growth of the CB cells together with an optimized cytokine cocktail developed specifically for MK differentiation, expansion, and maturation. Methodologies for flow cytometry analysis, MK and platelets estimation, and MK progenitor assay are also presented.


Blood Platelets/cytology , Cell Differentiation , Colony-Forming Units Assay/methods , Fetal Blood/cytology , Megakaryocytes/cytology , Stem Cells/cytology , Antigens, CD34/metabolism , Cell Culture Techniques , Cell Separation , Cryopreservation , Flow Cytometry , Humans , Megakaryocytes/metabolism , Ploidies , Stem Cells/metabolism
4.
Stem Cells Dev ; 21(17): 3209-19, 2012 Nov 20.
Article En | MEDLINE | ID: mdl-22783996

Umbilical cord blood (UCB) transplantation is associated with prolonged periods of cytopenia. Ex vivo expansion of hematopoietic stem and progenitor cells (HSPCs) is currently investigated as a mean to accelerate hematological recovery. Contrary to neutrophils, platelet recovery remains problematic. For this reason, we have developed a culture protocol promoting the expansion of megakaryocyte (Mk) progenitors. The objective of this work was to determine whether the expanded (E) UCB HSPCs could accelerate platelet recovery in vivo using a murine HSPC transplantation model. The thrombopoietic activity of UCB and mobilized peripheral blood CD34(+) cells expanded under mild hyperthermia (MH, ie, 39°C) with the optimized megakaryocyte progenitor cocktail (OMPC) diverged significantly from the nonexpanded (NE) cells of origin; E cells provided rapid platelet release, while NE cells strongly contributed to platelet production past 10 days of transplantation. Consequently, the complementary of both cell sources was investigated. Cotransplantation of NE with E UCB cells significantly improved the recovery of human platelets (hPLTs) in vivo due to their complementary and synergistic thrombopoietic activities. Moreover, short-term human bone marrow (BM) reconstitution was also improved. Finally, we show that early hPLT release is dependent on Mk-primed cells and that E cells do not act as accessory cells, but have a more active role. In conclusion, hPLT recovery and short-term BM engraftment can be efficiently improved by the cotransplantation of Mk-primed UCB cells with NE HSPCs in a murine transplantation model.


Blood Platelets/cytology , Cell Proliferation , Cord Blood Stem Cell Transplantation/methods , Fetal Blood/metabolism , Hematopoietic Stem Cell Transplantation/methods , Hematopoietic Stem Cells/metabolism , Adult , Animals , Antigens, CD34/metabolism , Blood Platelets/metabolism , Bone Marrow/metabolism , Bone Marrow/pathology , Cell Culture Techniques , Cells, Cultured , Disease Models, Animal , Fetal Blood/transplantation , Flow Cytometry , Hematopoietic Stem Cells/cytology , Hot Temperature , Humans , Megakaryocyte Progenitor Cells/cytology , Megakaryocyte Progenitor Cells/metabolism , Mice , Mice, Inbred NOD , Platelet Count , Platelet Membrane Glycoprotein IIb/metabolism , Thrombopoiesis
5.
Stem Cells Dev ; 21(17): 3197-208, 2012 Nov 20.
Article En | MEDLINE | ID: mdl-22564002

Hyperthermia treatment has at times been associated with increased platelet levels in humans. The heat shock protein HSP70, which can be induced by hyperthermia in megakaryocytes and erythrocytes, was recently shown to protect GATA-1 from degradation and to be required for erythroid differentiation. Based on these findings, we hypothesize that mild hyperthermia (MH), such as fever (39°C), could impact the differentiation of hematopoietic progenitors into erythrocytes and their subsequent maturation. Cell growth and erythroid differentiation increased dramatically in cord blood CD34(+) cell cultures incubated under MH. Erythroid maturation was also strongly promoted, which resulted in an increased proportion of hemoglobinized and enucleated erythroids. The rise in erythroid development was traced to a strong synergistic activity between MH and erythropoietin (EPO). The molecular basis for this potent synergy appears to originate from the capacity of MH to increase the basal activation of several signaling molecules downstream of the EPO receptor and the transcriptional activity of GATA-1. Moreover, the potent impact of MH on erythroid development was found be dependent on increased intracellular levels of reactive oxygen species. Thus, fever-like temperatures can promote the differentiation of progenitors along the erythroid lineage and accelerate their maturation through normal regulatory circuitry.


Cell Differentiation , Cell Proliferation , Erythroid Cells/cytology , Fetal Blood/cytology , Hot Temperature , Antigens, CD34/metabolism , Apoptosis , Cell Count , Cell Cycle , Cell Nucleus , Cells, Cultured , Erythroid Cells/metabolism , Erythropoiesis , Erythropoietin/metabolism , Fetal Blood/metabolism , Flow Cytometry , GATA1 Transcription Factor/genetics , GATA1 Transcription Factor/metabolism , Hematopoietic Stem Cells , Humans , Reactive Oxygen Species/metabolism , Receptors, Erythropoietin/metabolism , Transcriptional Activation
6.
Transfusion ; 51 Suppl 4: 72S-81S, 2011 Nov.
Article En | MEDLINE | ID: mdl-22074630

BACKGROUND: Thrombocytopenia is a serious side effect following high-dose chemotherapy or whole-body irradiation. For many patients, a hematopoietic stem cell (HSC) transplant is required as part of the treatment or to restore the integrity of the hematopoietic system. In this article, we first review the origin of thrombocytopenia in the context of umbilical cord blood (UCB) transplantation and current cellular therapies developed to overcome this condition. Results obtained in recent clinical trials and in the laboratory using a mouse-based xenograft model were also discussed. Second, we investigate the kinetic of human platelet production in two immunodeficient mouse strains transplanted with UCB cells to determine which of the two is better suited to measure the thrombopoietic potential of human hematopoietic cells. STUDY DESIGN AND METHODS: NOD/SCID/IL2Rγ(null) or NOD.CB17-Prkdcscid/NcrCrl (NOD/SCID) mice were transplanted with ex vivo expanded UCB cells. Human platelet levels and marrow engraftments were measured by cytometry analyses. RESULTS: Human platelets appeared earlier and at greater levels in the NOD/SCID/IL2Rγ(null) mouse strain. Consistent with these results and previous reports, human marrow engraftment was also greater in the IL2Rγ(null) -based NOD/SCID mice. CONCLUSION: The NOD/SCID/IL2Rγ(null) mouse strain is an ideal choice for preclinical studies aimed at measuring the in vivo thrombopoietic potential of human HPCs. Exploitation of such a model should facilitate the development of new cellular therapies aimed at improving hematological recoveries following HSC transplantation.


Cord Blood Stem Cell Transplantation , Thrombocytopenia/surgery , Animals , Disease Models, Animal , Flow Cytometry , Graft Survival , Hematopoietic Stem Cell Mobilization , Humans , Interleukin Receptor Common gamma Subunit/deficiency , Mice , Mice, Inbred NOD , Mice, SCID , Platelet Count , Radiation Chimera , Thrombocytopenia/physiopathology , Transplantation, Heterologous
7.
Stem Cells Dev ; 20(3): 379-90, 2011 Mar.
Article En | MEDLINE | ID: mdl-20504152

The development of culture processes for hematopoietic progenitors could lead to the development of a complementary source of platelets for therapeutic purposes. However, functional characterization of culture-derived platelets remains limited, which raises some uncertainties about the quality of platelets produced in vitro. The aim of this study was to define the proportion of functional platelets produced in cord blood CD34+ cell cultures. Toward this, the morphological and functional properties of culture-derived platelet-like particles (PLPs) were critically compared to that of blood platelets. Flow cytometry combined with transmission electron microscopy analyses revealed that PLPs formed a more heterogeneous population of platelets at a different stage of maturation than blood platelets. The majority of PLPs harbored the fibrinogen receptor αIIbß3, but a significant proportion failed to maintain glycoprotein (GP)Ibα surface expression, a component of the vWF receptor essential for platelet functions. Importantly, GPIbα extracellular expression correlated closely with platelet function, as the GPIIb+ GPIbα+ PLP subfraction responded normally to agonist stimulation as evidenced by α-granule release, adhesion, spreading, and aggregation. In contrast, the GPIIb+ GPIbα⁻ subfraction was unresponsive in most functional assays and appeared to be metabolically inactive. The present study confirms that functional platelets can be generated in cord blood CD34+ cell cultures, though these are highly susceptible to ectodomain shedding of receptors associated with loss of function. Optimization of culture conditions to prevent these deleterious effects and to homogenize PLPs is necessary to improve the quality and yields of culture-derived platelets before they can be recognized as a suitable complementary source for therapeutic purposes.


Blood Platelets/cytology , Blood Platelets/metabolism , Platelet Glycoprotein GPIb-IX Complex/metabolism , Antigens, CD34/metabolism , Cell Aggregation , Cell Culture Techniques/methods , Cell Shape , Cell Size , Cells, Cultured , Culture Media, Serum-Free , Cytokines/metabolism , Fetal Blood/cytology , Fibrinogen/metabolism , Humans , Megakaryocytes/cytology , P-Selectin/metabolism , Phalloidine/metabolism , Protein Stability , Pseudopodia/metabolism , Signal Transduction
8.
Cytotherapy ; 13(4): 467-80, 2011 Apr.
Article En | MEDLINE | ID: mdl-21090916

BACKGROUND AIMS: Expansion of hematopoietic progenitors ex vivo is currently investigated as a means of reducing cytopenia following stem cell transplantation. The principal objective of this study was to develop a new cytokine cocktail that would maximize the expansion of megakaryocyte (Mk) progenitors that could be used to reduce periods of thrombocytopenia. METHODS: We measured the individual and synergistic effects of six cytokines [stem cell factor (SCF), FLT-3 ligand (FL), interleukin (IL)-3, IL-6, IL-9 and IL-11] commonly used to expand cord blood (CB) CD34(+) cells on the expansion of CB Mk progenitors and major myeloid populations by factorial design. RESULTS: These results revealed an elaborate array of cytokine individual effects complemented by a large number of synergistic and antagonistic interaction effects. Notably, strong interactions with SCF were observed with most cytokines and its concentration level was the most influential factor for the expansion and differentiation kinetics of CB CD34(+) cells. A response surface methodology was then applied to optimize the concentrations of the selected cytokines. The newly developed cocktail composed of SCF, thrombopoietin (TPO) and FL increased the expansion of Mk progenitors and maintained efficient expansion of clonogenic progenitors and CD34(+) cells. CB cells expanded with the new cocktail were shown to provide good short- and long-term human platelet recovery and lymphomyeloid reconstitution in NOD/SCID mice. CONCLUSIONS: Collectively, these results define a complex cytokine network that regulates the growth and differentiation of immature and committed hematopoietic cells in culture, and confirm that cytokine interactions have major influences on the fate of hematopoietic cells.


Antigens, CD34/metabolism , Cytokines/pharmacology , Fetal Blood/cytology , Megakaryocyte Progenitor Cells/cytology , Megakaryocyte Progenitor Cells/drug effects , Animals , Drug Synergism , Flow Cytometry , Humans , Interleukin-11/pharmacology , Interleukin-3/pharmacology , Interleukin-6/pharmacology , Interleukin-9/pharmacology , Membrane Proteins/pharmacology , Mice , Mice, Inbred NOD , Mice, SCID , Stem Cell Factor/pharmacology
9.
Cell Cycle ; 9(13): 2589-99, 2010 Jul 01.
Article En | MEDLINE | ID: mdl-20647776

Megakaryocytes (MK) undergo polyploidization through endomitosis, a mitotic process that ends prematurely due to aborted cytokinesis. To better understand this and other events associated with MK differentiation, we performed long-term and large-field live cell imaging of human MKs derived in cord blood (CB) and bone marrow (BM) CD34(+) cell cultures. Polyploid level of imaged cells was evaluated using three complementary approaches; cell history, cell size and ploidy correlation and nuclei staining. This system and strategy enabled the direct observation of the development of a large number of MKs (n=4865) and to quantify their fates. The most significant finding of this study is that a considerable proportion of polyploid MKs could complete cytokinesis. This unexpected process gave rise to polyploid daughter cell(s) with normal fates and contributed significantly to the expansion of polyploid MKs. Further analyses revealed that the proliferation rate amongst polyploid MKs was inversely correlated to their ploidy level, and that this phenomenon was much more frequent in CB- than BM-derived MKs. Accordingly, endomitosis was identified as the dominant fate of polyploid BM-MKs, while this was less accentuated for polyploid CB-MKs. These findings explain partially why CB-derived MKs remain in lower ploidy class. In conclusion, this study demonstrates that the development of polyploid MK results from the failure and/or success of cytokinesis and brings a new paradigm to the field of megakaryopoiesis.


Cytokinesis , Megakaryocytes/cytology , Polyploidy , Adult , Antigens, CD34/metabolism , Bone Marrow Cells/cytology , Cell Lineage , Cell Size , Cell Survival , Cells, Cultured , Fetal Blood/cytology , Humans , Imaging, Three-Dimensional , Mitosis , Mitotic Index , Models, Biological , Thrombopoietin/metabolism
10.
Stem Cells Dev ; 17(3): 483-93, 2008 Jun.
Article En | MEDLINE | ID: mdl-18522497

The physical culture parameters have important influences on the proliferation and differentiation fate of hematopoietic stem cells. Recently, we have demonstrated that CD34+ cord blood (CB) cells undergo accelerated and increased megakaryocyte (Mk) differentiation when incubated under mild hyperthermic conditions (i.e., 39 degrees C). In this study, we investigated in detail the impacts of mild hyperthermia on Mk differentiation and maturation, and explored potential mechanisms responsible for these phenomena. Our results demonstrate that the qualitative and quantitative effects on Mk differentiation at 39 degrees C appear rapidly within 7 days, and that early transient culture at 39 degrees C led to even greater Mk yields (p<0.03). Surprisingly, cell viability was only found to be significantly reduced in the early stages of culture, suggesting that CB cells are able with time to acclimatize themselves to 39 degrees C. Although mild hyperthermia accelerated differentiation and maturation of CB-derived Mks, it failed to promote their polyploidization further but rather led to a small reduction in the proportion of polyploid Mks (p=0.01). Conversely, gene arrays analysis demonstrated that Mks derived at 39 degrees C have a normal gene expression program consistent with an advanced maturation state. Finally, two independent mechanisms that could account for the accelerated Mk differentiation were investigated. Our results suggest that the accelerated and increased Mk differentiation induced by mild hyperthermia is not mediated by cell-secreted factors but could perhaps be mediated by the increased expression of Mk transcription factors.


Cell Differentiation , Heat-Shock Response , Megakaryocytes/cytology , Cell Differentiation/drug effects , Cell Survival/drug effects , Cells, Cultured , Cytokines/pharmacology , Fetal Blood/cytology , Fetal Blood/drug effects , Gene Expression Regulation/drug effects , Heat-Shock Response/drug effects , Humans , Megakaryocytes/drug effects , Oligonucleotide Array Sequence Analysis , Platelet-Derived Growth Factor/pharmacology , Polyploidy , RNA, Messenger/genetics , RNA, Messenger/metabolism , Reproducibility of Results , Temperature , Transcription Factors/genetics , Transcription Factors/metabolism
11.
J Immunol Methods ; 332(1-2): 82-91, 2008 Mar 20.
Article En | MEDLINE | ID: mdl-18234208

Expansion of hematopoietic progenitor cells (HPC) ex vivo remains an important focus in fundamental and clinical research. The aim of this study was to determine whether the implementation of such expansion phase in a two-phase culture strategy prior to the induction of megakaryocyte (Mk) differentiation would increase the yield of Mks produced in cultures. Toward this end, we first characterized the functional properties of five cytokine cocktails to be tested in the expansion phase on the growth and differentiation kinetics of CD34+-enriched cells, and on their capacity to expand clonogenic progenitors in cultures. Three of these cocktails were chosen based on their reported ability to induce HPC expansion ex vivo, while the other two represented new cytokine combinations. These analyses revealed that none of the cocktails tested could prevent the differentiation of CD34+ cells and the rapid expansion of lineage-positive cells. Hence, we sought to determine the optimum length of time for the expansion phase that would lead to the best final Mk yields. Despite greater expansion of CD34+ cells and overall cell growth with a longer expansion phase, the optimal length for the expansion phase that provided greater Mk yield at near maximal purity was found to be 5 days. Under such settings, two functionally divergent cocktails were found to significantly increase the final yield of Mks. Surprisingly, these cocktails were either deprived of thrombopoietin or of stem cell factor, two cytokines known to favor megakaryopoiesis and HPC expansion, respectively. Based on these results, a short resource-efficient two-phase culture protocol for the production of Mks near purity (>95%) from human CD34+ CB cells has been established.


Antigens, CD34/immunology , Fetal Blood/cytology , Megakaryocytes/cytology , Cell Culture Techniques/methods , Cell Differentiation/drug effects , Cell Differentiation/immunology , Cell Proliferation/drug effects , Cytokines/pharmacology , Fetal Blood/immunology , Flow Cytometry/methods , Humans , Kinetics , Megakaryocytes/drug effects , Megakaryocytes/immunology , Time Factors
12.
J Immunol Methods ; 322(1-2): 118-27, 2007 Apr 30.
Article En | MEDLINE | ID: mdl-17397859

Adenoviral gene transfer into human B lymphocytes and haematopoietic progenitors would allow the characterization of their function on cellular growth, differentiation and survival. Efficient gene expression is however strongly dependent on the promoter used. In this study, we investigated the relative strength of various promoters by following and measuring the expression of the reporter gene EYFP in human peripheral B lymphocytes, cord blood CD34(+) cells and the megakaryocytic cell line M-07e. The murine PGK promoter provided the best level of transgene expression in CD34(+) cells among the four promoters tested, followed closely by the CMV promoter, and to a lesser extend by a CMV promoter with a beta-globin/IgG chimeric intron, whereas the human CD40 promoter provided the lowest levels of expression. In contrast, the strongest promoters in B lymphocytes were the two CMV promoters. Surprisingly, even the best promoters were unable to induce transgene expression in more than 75-80% of the primary B and CD34(+) cells, even though 100% of the cells were infected. Finally and in contrast to retroviruses, only a minority of B lymphocytes and CD34(+) cells were able to induce the transcription of IRES-containing bicistronic expression cassettes from adenovirus.


B-Lymphocytes/metabolism , Hematopoietic Stem Cells/metabolism , Promoter Regions, Genetic/genetics , Transgenes/genetics , Adenoviridae/genetics , Animals , Cytomegalovirus/genetics , Exoribonucleases , Gene Transfer Techniques , Humans , Mice , Proteins/genetics , Repressor Proteins , Ribonucleases , Transcription, Genetic
13.
Exp Hematol ; 33(10): 1182-91, 2005 Oct.
Article En | MEDLINE | ID: mdl-16219540

OBJECTIVE: A multi-step statistical strategy was applied to quantify individual and interactive effects of cytokines on megakaryopoiesis and to determine the concentration of the selected cytokines that optimize ex vivo megakaryocyte (MK) expansion, maturation, and platelet production in stromal- and serum-free conditions. MATERIALS AND METHODS: Immature MK were first generated from human CD34(+)-enriched cord blood cells cultured for 7 days in conditions favoring MK commitment. Then, the effect of different combinations of cytokines at various concentrations on MK differentiation and platelet production was tested on the day-7 MK. RESULTS: A large-scale screening of 13 cytokines in the presence of thrombopoietin (TPO) using Placket-Burman designs (PBD) was initially performed to identify stimulators of MK maturation. Afterwards, a statistical analysis of the two-level factorial designs revealed that in the presence of TPO, MK maturation was significantly stimulated by stem cell factor (SCF), interleukin (IL)-6, and IL-9, whereas Flt-3 ligand (FL) had a positive effect only on the expansion of MK progenitors. In contrast, erythropoietin (EPO) and IL-8 were inhibitors of MK maturation. A response surface methodology was then used to optimize the concentrations of the selected cytokines (TPO, SCF, IL-6, and IL-9) and defined a new cytokine cocktail that maximized MK expansion and maturation. Importantly, the increased MK output was accompanied by a very high MK purity ( approximately 90%). Another optimum was also found at a higher SCF concentration, which further improved MK expansion and maturation, but reduced MK purity. CONCLUSION: These statistical methods provide an efficient tool to analyze complex systems of cytokines and to develop promising ex vivo MK culture systems for clinical applications.


Blood Platelets/physiology , Cell Differentiation/drug effects , Cytokines/pharmacology , Fetal Blood/physiology , Megakaryocytes/physiology , Thrombopoiesis/drug effects , Blood Platelets/cytology , Cell Differentiation/physiology , Cells, Cultured , Drug Combinations , Fetal Blood/cytology , Humans , Megakaryocytes/cytology , Research Design , Thrombopoiesis/physiology
14.
Biotechnol Bioeng ; 88(6): 675-80, 2004 Dec 20.
Article En | MEDLINE | ID: mdl-15532059

Based on previous evidence suggesting positive effects of fever on in vivo hematopoiesis, we tested the effect of hyperthermia on megakaryopoiesis (MK) in ex vivo cultures of CD34-enriched cord blood (CB) cells. The cells were cultured at 37 degrees C or 39 degrees C for 14 days in cytokine conditions optimized for megakaryocyte development and analyzed periodically. Compared to 37 degrees C, the cultures maintained at 39 degrees C produced significantly more (up to 10-fold) total cells, myeloid and MK progenitors, and total MKs, and showed accelerated and enhanced MK maturation with increased yields of proplatelets and platelets. This observation could facilitate clinical applications requiring ex vivo expansion of hematopoietic cells.


Antigens, CD34/metabolism , Blood Platelets/cytology , Blood Platelets/physiology , Cell Culture Techniques/methods , Fetal Blood/cytology , Megakaryocytes/cytology , Megakaryocytes/physiology , Temperature , Cell Differentiation/physiology , Cells, Cultured , Hematopoietic Stem Cells/cytology , Hematopoietic Stem Cells/physiology , Humans , Infant, Newborn
15.
J Hematother Stem Cell Res ; 12(2): 179-88, 2003 Apr.
Article En | MEDLINE | ID: mdl-12804177

The high proliferative potential of cord blood (CB) stem cells and the identification of the key factor of megakaryopoiesis, thrombopoietin (TPO), permit the ex vivo expansion of megakaryocytes (MKs) for possible use in early post-transplant support of patients and the production of functional platelets for transfusion. However, culture conditions for the generation of adequate MKs for this purpose are not yet optimized. Therefore, we sought to define the mixture of early-acting cytokines and TPO that would promote the expansion of MK progenitors over other lineages and result in overall better MK expansion and platelet yields. CB CD34(+)-enriched cells were cultured in serum-free medium for 17 days in presence of TPO alone or in various combinations with early-acting cytokines used at different concentrations and addition times. MK expansion and polyploidy and platelet production were monitored by flow cytometry analysis using specific surface markers (CD41 and CD42b) and propidium iodide labeling. Our results showed that the use of high concentrations of stem cell factor (SCF) and Flt-3 ligand (FL) in early CB TPO-supplemented cultures was more favorable to monocytic and granulocytic cell expansion. However, we observed that their presence in limiting amounts was required for the preferential expansion of MK progenitors. The addition of SCF, FL, TPO, and interleukin-6 (IL-6) at high concentrations in secondary cultures of these expanded MKs resulted in optimal MK proportion (approximately 25% of MKs) and expansion (>300 MK per seeded cell), highest proportions of polyploid MKs (22% of mature MKs > or = 8N), and best platelet yields. Our results indicate that TPO-induced MK progenitors are more sensitive to early-acting cytokines than non-MK cells. We propose that MKs generated in the optimized conditions, in combination with immature stem/progenitor cells, could prove useful for the short-term platelet recovery following CB transplantation.


Cell Culture Techniques/methods , Fetal Blood/cytology , Growth Substances/pharmacology , Megakaryocytes/cytology , Antigens, CD34 , Cell Differentiation/drug effects , Cell Division/drug effects , Drug Interactions , Fetal Blood/drug effects , Humans , Interleukin-6/pharmacology , Membrane Proteins/pharmacology , Stem Cell Factor/pharmacology , Thrombopoietin/pharmacology
16.
Transfusion ; 42(1): 59-65, 2002 Jan.
Article En | MEDLINE | ID: mdl-11896314

BACKGROUND: In blood banks, D MoAbs are routinely used to phenotype donors and patients. However, most D MoAbs do not agglutinate RBCs that weakly express D. The use of higher affinity MoAbs could overcome this problem. In this work, an attempt has been made to increase the affinity of the human clone 43F10, an IgG anti-D, by light (L)-chain shuffling followed by selection using phage display. STUDY DESIGN AND METHODS: PBMNCs of three polyimmunized individuals were used to construct the kappa L-chain repertoire that was recombined with the 43F10 heavy chain in a phagemid vector system (pComb3H, Scripps Institute, La Jolla, CA). L-chain-shuffled 43F10-F(ab) phages were selected on intact RBCs and characterized by ELISA, indirect agglutination, and sequence analysis. RESULTS: L-chain shuffling combined with phage display permitted the selection of a 43F10 MoAb variant (p3.17) with improved reactivity with weak D RBCs in agglutination assays. Nucleic acid sequence analysis showed that p3.17 and wild-type (wt) 43F10 L chains are encoded by different VL segments of the Vk1 family and different J segments, thus showing a relatively low degree of homology (86.4%). CONCLUSION: The use of a variant such as p3.17 could permit a further increase of the potency of existing anti-D reagents. The low homology between p3.17 and wt 43F10 sequences further exemplifies the predominant role of the heavy chain in determining the specificity of the anti-D.


Antibodies, Monoclonal/immunology , Bacteriophages/genetics , Immunoglobulin kappa-Chains/immunology , Isoantibodies/immunology , Amino Acid Sequence , Animals , Antibodies, Monoclonal/genetics , Antibody Affinity , Blood Grouping and Crossmatching , Gene Library , Gene Rearrangement, B-Lymphocyte, Light Chain , Humans , Hybridomas/immunology , Immunoglobulin Fab Fragments/immunology , Immunoglobulin kappa-Chains/genetics , Immunosorbent Techniques , Isoantibodies/genetics , Mice , Molecular Sequence Data , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/immunology , Rho(D) Immune Globulin , Sequence Alignment , Sequence Analysis, DNA , Sequence Homology, Amino Acid
17.
Blood ; 99(4): 1267-72, 2002 Feb 15.
Article En | MEDLINE | ID: mdl-11830475

The prophylaxis of the hemolytic disease of the newborn requires significant amounts of plasma-derived polyclonal human anti-D. Because of procurement problems, there is a growing interest in replacing plasma-derived anti-D by in vitro-produced human monoclonal anti-D. Hundreds of monoclonal anti-D have been prepared, but the selection of the most potent for in vivo use is difficult because it cannot be predicted by in vitro characterization. This study evaluated the possibility of using nonobese diabetic/severe combined immunodeficient (NOD-scid) mice for the in vivo evaluation of human monoclonal anti-D. Human red blood cells (RBCs) were found to circulate normally in the blood of NOD-scid mice previously injected with a physiologic amount of human immunoglobulin G (10 mg). The addition of a small amount of anti-D (1 to 5 microg) resulted in the clearance of Rh D(+) RBCs within 4 hours. The comparative testing of 8 monoclonal anti-Ds showed a wide range of potency (15% to 87%) relative to plasma-derived polyclonal anti-D. There was no strong correlation between the in vivo potency index and the immunoglobulin G isotype, affinity, or fine specificity of the antibodies. These results show the usefulness of NOD-scid mice for the initial in vivo screening of human monoclonal anti-D before testing the most active antibodies in clinical trials done in human volunteers.


Isoantibodies/pharmacology , Rh-Hr Blood-Group System/immunology , Animals , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/pharmacology , Antibody Affinity , Antibody Specificity , Cell Survival/immunology , Drug Evaluation, Preclinical/methods , Erythrocyte Transfusion , Erythrocytes/immunology , Hemolysis/immunology , Humans , Immunoglobulin G/administration & dosage , Immunoglobulin G/pharmacology , Immunoglobulin Isotypes/administration & dosage , Immunoglobulin Isotypes/pharmacology , Isoantibodies/administration & dosage , Mice , Mice, Inbred NOD , Mice, SCID , Rho(D) Immune Globulin
...